Terminal Cancer - San Pedro CA (Metro Los Angeles)

Summary:

The end-stage cancer patients do not have options for curative therapies, and their function and quality of life is poor, however, 145 patients treated by a pilot therapy of the quercetin showed a positive result in their markers with good safety records.

A non-randomized single-arm Pilot design in which each patient will have either low life expectancy due to the aggressive nature of his/her Tumor or failed the prior chemotherapy and will act as their own control.

In this study, the trial is aiming to show improved quality of life outcome measures and therefore the trial is not tumor type specific. The secondary endpoints are related to surrogates of survival/angiogenesis ( VEGF and CTC), and therefore again not tumor type specific.

Qualified Participants Must:

• 1. Be 18 years or older
• 2. Sign IRB approved consent before any study procedures are done.
• 3. Diagnosed with Stage IV solid Tumor
• 4. Have an ECOG performance status of 0-2.
• 5. Have a life expectancy of at least three months
• 6. Have no conventional curative options of care available or refuse them
• 7. Have at least one objectively evaluable tumor, by radiologic imaging or a visible cutaneous lesion
• 8. Be non-pregnant. Female patients must be surgically sterile, post-menopausal or practicing an approved method of birth control. In addition, female patients of childbearing potential must have a negative serum pregnancy test
• 9. Have the following laboratory parameters:

• Absolute granulocyte count of 1000/mm3 or more
• Hemoglobin of 8 gram/dl or more
• Absolute lymphocyte count of 400/mm3 or more
• Prothrombin time of less than 1.5 X control
• Partial thromboplastin time less than 1.5 X control
• Creatinine less than 2.0 mg/dl
• Bilirubin less than X 4.0 normal
• Serum albumin of more than 2.0 grams/dl

Qualified Participants May Receive:

The sponsor of the study will pay for the treatments.